Based on ratings from 10 stock analysts, the ResMed Inc stock price is expected to increase by 1.66% in 12 months. This is calculated by using the average 12-month stock price forecast for ResMed Inc. The lowest target is $190 and the highest is $283. Please note analyst price targets are not guaranteed and could be missed completely.
About 10 Wall Street analysts have assigned RMD 4 buy ratings, 2 hold ratings, and 4 sell ratings. This means that analysts expect ResMed Inc to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on RMD. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of RMD.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Brett Fishbin Keybanc | Overweight | $266 | Maintains | Oct 25, 2024 |
Joe Vruwink Baird | Outperform | $283 | Maintains | Oct 25, 2024 |
Craig Wong-Pan RBC Capital | Sector Perform | $232 | Maintains | Oct 25, 2024 |
Mike Matson Needham | Hold | Reiterates | Oct 25, 2024 | |
Craig Wong-Pan RBC Capital | Sector Perform | $224 | Maintains | Oct 1, 2024 |
Mike Matson Needham | Hold | Reiterates | Oct 1, 2024 | |
Lyanne Harrison B of A Securities | Buy | $270 | Maintains | Sep 26, 2024 |
Joe Vruwink Baird | Outperform | $280 | Initiates | Sep 24, 2024 |
Mike Matson Needham | Hold | Reiterates | Sep 18, 2024 | |
Mike Polark Wolfe Research | Underperform | $180 | Downgrade | Sep 18, 2024 |
Mike Matson Needham | Hold | $236 | Downgrade | Sep 4, 2024 |
Mike Matson Needham | Buy | $236 | Reiterates | Aug 2, 2024 |
Craig Wong-Pan RBC Capital | Sector Perform | $206 | Maintains | Aug 2, 2024 |
Brett Fishbin Keybanc | Overweight | $251 | Maintains | Aug 2, 2024 |
Craig Wong-Pan RBC Capital | Sector Perform | $204 | Maintains | Jul 23, 2024 |
Suraj Kalia Oppenheimer | Perform | Downgrade | Jun 25, 2024 | |
Mike Matson Needham | Buy | $236 | Reiterates | Jun 24, 2024 |
Mathieu Chevrier Citigroup | Neutral | Downgrade | Jun 24, 2024 | |
Brett Fishbin Keybanc | Overweight | $238 | Maintains | Apr 26, 2024 |
Suraj Kalia Oppenheimer | Outperform | $200 | Maintains | Apr 26, 2024 |
When did it IPO
1995
Staff Count
9,980
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Michael J. Farrell BE, MBA, SM
Market Cap
$36.06B
In 2023, RMD generated $4.22B in revenue, which was a increase of 18.02% from the previous year. This can be seen as a signal that RMD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - ResMed's CEO Mick Farrell and CMO Dr. Carlos Nunez will speak at the UBS Global Healthcare Conference on November 12, 2024, at 3:30 PM PST in Rancho Palos Verdes, CA.
Why It Matters - The participation of ResMed's CEO and CMO in a major healthcare conference highlights the company's visibility and potential growth opportunities, influencing investor sentiment and stock performance.
Summary - Zacks Premium research service offers Zacks Style Scores, facilitating stock selection for value, growth, and momentum investors.
Why It Matters - Zacks Style Scores enhance stock selection by identifying strong candidates across investment strategies, potentially leading to better returns and informed investment decisions.
Summary - ResMed (RMD) shows strong growth potential, indicating it may outperform the market.
Why It Matters - ResMed's strong growth attributes suggest potential for higher returns, indicating it may outperform competitors, attracting investor interest and possibly boosting stock performance.
Summary - The SPDR S&P 500 ETF Trust fell 0.89% in October. Top 15 dividend growth stocks for November 2024 show a 1.24% yield and are 23% undervalued, with an 11.33% CAGR since September 2020.
Why It Matters - The SPDR S&P 500 ETF's October loss signals potential market volatility, while undervalued dividend stocks may attract income-focused investors seeking growth amid uncertainty.
Summary - ResMed (RMD) CEO Mick Farrell announced the company exceeded earnings expectations, focusing on treatments for sleep apnea and COPD.
Why It Matters - ResMed's earnings beat indicates strong demand and effective management, signaling potential growth and profitability, which could positively influence stock performance.
Summary - ResMed (RMD) has reached a 52-week high. Investors may look into the company's fundamentals for insights on potential future gains.
Why It Matters - ResMed's 52-week high signals strong market performance, but analyzing its fundamentals will reveal potential for continued growth or risks, influencing investment decisions.